Mesoblast Analyst Ratings
Mesoblast Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/21/2023 | 1197.71% | Cantor Fitzgerald | → $17 | Reiterates | Overweight → Overweight |
| 08/31/2023 | — | Jefferies | Upgrades | Hold → Buy | |
| 08/31/2023 | 1197.71% | Cantor Fitzgerald | $23 → $17 | Maintains | Overweight |
| 08/07/2023 | — | Maxim Group | Downgrades | Buy → Hold | |
| 08/04/2023 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 08/04/2023 | 52.67% | Piper Sandler | $7 → $2 | Downgrades | Overweight → Neutral |
| 08/04/2023 | 14.5% | Chardan Capital | $2 → $1.5 | Maintains | Sell |
| 05/30/2023 | 52.67% | Chardan Capital | $2.5 → $2 | Maintains | Sell |
| 03/01/2023 | 90.84% | Chardan Capital | → $2.5 | Reiterates | → Sell |
| 02/01/2023 | 1655.73% | Cantor Fitzgerald | → $23 | Reiterates | → Overweight |
| 12/06/2022 | — | Jefferies | Downgrades | Buy → Hold | |
| 09/06/2022 | 434.35% | Piper Sandler | → $7 | Initiates Coverage On | → Overweight |
| 06/03/2022 | 90.84% | Chardan Capital | $6.5 → $2.5 | Maintains | Sell |
| 08/31/2021 | 396.18% | Chardan Capital | $7.5 → $6.5 | Maintains | Sell |
| 04/07/2021 | — | Maxim Group | Upgrades | Hold → Buy | |
| 01/19/2021 | — | Jefferies | Downgrades | Buy → Hold | |
| 12/22/2020 | — | Maxim Group | Downgrades | Buy → Hold | |
| 12/04/2020 | 472.52% | Chardan Capital | $5.5 → $7.5 | Downgrades | Neutral → Sell |
| 11/20/2020 | 1426.72% | HC Wainwright & Co. | $19 → $20 | Maintains | Buy |
| 10/22/2020 | 816.03% | RBC Capital | → $12 | Initiates Coverage On | → Sector Perform |
| 10/02/2020 | 1350.38% | HC Wainwright & Co. | $21 → $19 | Maintains | Buy |
| 05/28/2020 | 1503.05% | HC Wainwright & Co. | $14 → $21 | Reiterates | → Buy |
| 10/22/2019 | 1655.73% | Cantor Fitzgerald | → $23 | Assumes | → Overweight |
| 01/31/2019 | 396.18% | HC Wainwright & Co. | → $6.5 | Assumes | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023年09月21日 | 1197.71% | 康托·菲茨杰拉德 | →$17 | 重申 | 超重→超重 |
| 2023年08月31日 | - | 杰富瑞 | 升级 | 持有→购买 | |
| 2023年08月31日 | 1197.71% | 康托·菲茨杰拉德 | $23→$17 | 维护 | 超重 |
| 08/07/2023 | - | Maxim集团 | 评级下调 | 购买→Hold | |
| 08/04/2023 | - | 威廉·布莱尔 | 评级下调 | 跑赢→市场表现 | |
| 08/04/2023 | 52.67% | 派珀·桑德勒 | $7→$2 | 评级下调 | 超重→中性 |
| 08/04/2023 | 14.5% | 查尔丹资本 | $2→$1.5 | 维护 | 卖 |
| 2023年05月30日 | 52.67% | 查尔丹资本 | $2.5→$2 | 维护 | 卖 |
| 03/01/2023 | 90.84% | 查尔丹资本 | →$2.5 | 重申 | →销售 |
| 02/01/2023 | 1655.73% | 康托·菲茨杰拉德 | →$23 | 重申 | →超重 |
| 12/06/2022 | - | 杰富瑞 | 评级下调 | 购买→Hold | |
| 09/06/2022 | 434.35% | 派珀·桑德勒 | →$7 | 开始承保 | →超重 |
| 06/03/2022 | 90.84% | 查尔丹资本 | $6.5→$2.5 | 维护 | 卖 |
| 2021/08/31 | 396.18% | 查尔丹资本 | $7.5→$6.5 | 维护 | 卖 |
| 04/07/2021 | - | Maxim集团 | 升级 | 持有→购买 | |
| 2021/01/19 | - | 杰富瑞 | 评级下调 | 购买→Hold | |
| 12/22/2020 | - | Maxim集团 | 评级下调 | 购买→Hold | |
| 12/04/2020 | 472.52% | 查尔丹资本 | $5.5→$7.5 | 评级下调 | 中性→销售 |
| 11/20/2020 | 1426.72% | HC Wainwright公司 | $19→$20 | 维护 | 买 |
| 10/22/2020 | 816.03% | 加拿大皇家银行资本 | →$12 | 开始承保 | →行业表现 |
| 10/02/2020 | 1350.38% | HC Wainwright公司 | $21→$19 | 维护 | 买 |
| 05/28/2020 | 1503.05% | HC Wainwright公司 | $14→$21 | 重申 | →购买 |
| 2019年10月22日 | 1655.73% | 康托·菲茨杰拉德 | →$23 | 假设 | →超重 |
| 2019年01月31日 | 396.18% | HC Wainwright公司 | →$6.5 | 假设 | →购买 |
What is the target price for Mesoblast (MESO)?
中胚层(Meso)的目标价是多少？
The latest price target for Mesoblast (NASDAQ: MESO) was reported by Cantor Fitzgerald on September 21, 2023. The analyst firm set a price target for $17.00 expecting MESO to rise to within 12 months (a possible 1197.71% upside). 11 analyst firms have reported ratings in the last year.
坎托·菲茨杰拉德于2023年9月21日报道了中胚层(纳斯达克：MESO)的最新目标价。这家分析公司将目标价定为17美元，预计Meso将在12个月内上涨(可能上涨1197.71%)。过去一年，有11家分析公司公布了评级。
What is the most recent analyst rating for Mesoblast (MESO)?
分析师对中胚层(Meso)的最新评级是什么？
The latest analyst rating for Mesoblast (NASDAQ: MESO) was provided by Cantor Fitzgerald, and Mesoblast reiterated their overweight rating.
中原地产(纳斯达克股票代码：MESO)的最新分析师评级由康托·菲茨杰拉德提供，中原地产重申其增持评级。
When is the next analyst rating going to be posted or updated for Mesoblast (MESO)?
中胚层(MESO)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Mesoblast, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Mesoblast was filed on September 21, 2023 so you should expect the next rating to be made available sometime around September 21, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Mesoblast的高管和客户交谈，以及收听收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。中胚层的最后一次评级是在2023年9月21日提交的，所以你应该预计下一次评级将在2024年9月21日左右的某个时候提供。
Is the Analyst Rating Mesoblast (MESO) correct?
分析师对中胚层细胞(Meso)的评级正确吗？
While ratings are subjective and will change, the latest Mesoblast (MESO) rating was a reiterated with a price target of $0.00 to $17.00. The current price Mesoblast (MESO) is trading at is $1.31, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的中胚层(Meso)评级被重申，目标价在0.00美元至17.00美元之间。中成纤维(Meso)目前的交易价格为1.31美元，在分析师的预测范围内。